Alan Lichtenstein

13.3k total citations · 3 hit papers
162 papers, 10.5k citations indexed

About

Alan Lichtenstein is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Alan Lichtenstein has authored 162 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Molecular Biology, 60 papers in Hematology and 57 papers in Oncology. Recurrent topics in Alan Lichtenstein's work include Multiple Myeloma Research and Treatments (57 papers), PI3K/AKT/mTOR signaling in cancer (30 papers) and Immune Cell Function and Interaction (20 papers). Alan Lichtenstein is often cited by papers focused on Multiple Myeloma Research and Treatments (57 papers), PI3K/AKT/mTOR signaling in cancer (30 papers) and Immune Cell Function and Interaction (20 papers). Alan Lichtenstein collaborates with scholars based in United States, Mexico and United Kingdom. Alan Lichtenstein's co-authors include Tomas Ganz, Joseph Gera, Yijiang Shi, Robert I. Lehrer, Yiping Tu, Elizabeta Nemeth, Gary J. Schiller, Patrick Frost, Mary Territo and Erika V. Valore and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Alan Lichtenstein

161 papers receiving 10.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

2003 1.2k citations Alan Lichtenstein, Tomas Ganz et al. profile →
Defensins: Antimicrobial and Cytotoxic Peptides of Mammalian Cells

1993 834 citations Robert I. Lehrer, Alan Lichtenstein et al. profile →
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 780 citations James R. Berenson, Alan Lichtenstein et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Alan Lichtenstein	4.8k	3.6k	3.3k	1.9k	1.3k	162	10.5k
Karl Welte	3.4k 0.7×	4.3k 1.2×	5.6k 1.7×	7.5k 4.0×	1.1k 0.8×	382	18.6k
Anders Sundan	3.5k 0.7×	2.0k 0.6×	1.8k 0.6×	3.0k 1.6×	369 0.3×	160	8.2k
Fionula M. Brennan	4.3k 0.9×	1.8k 0.5×	3.6k 1.1×	7.7k 4.1×	608 0.5×	172	17.5k
José L. Fernández-Luna	3.1k 0.6×	973 0.3×	2.0k 0.6×	2.3k 1.2×	749 0.6×	94	6.8k
Edo Vellenga	7.6k 1.6×	8.7k 2.4×	5.3k 1.6×	3.4k 1.8×	2.7k 2.0×	487	18.7k
Zwi Berneman	4.8k 1.0×	2.3k 0.7×	3.7k 1.1×	4.6k 2.5×	1.5k 1.2×	320	13.2k
Walter Knapp	2.9k 0.6×	1.9k 0.5×	1.6k 0.5×	6.0k 3.2×	836 0.6×	220	10.6k
Yoshiyuki Niho	2.4k 0.5×	2.3k 0.6×	1.9k 0.6×	2.9k 1.5×	822 0.6×	423	9.2k
B Perussia	3.0k 0.6×	1.7k 0.5×	2.5k 0.8×	10.5k 5.6×	599 0.5×	132	14.3k
Thomas S. Edgington	4.0k 0.8×	6.0k 1.7×	1.2k 0.4×	2.9k 1.5×	1.9k 1.5×	204	14.4k

Countries citing papers authored by Alan Lichtenstein

Since Specialization

Citations

This map shows the geographic impact of Alan Lichtenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lichtenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lichtenstein more than expected).

Fields of papers citing papers by Alan Lichtenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Lichtenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lichtenstein. The network helps show where Alan Lichtenstein may publish in the future.

Co-authorship network of co-authors of Alan Lichtenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Lichtenstein. A scholar is included among the top collaborators of Alan Lichtenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Lichtenstein. Alan Lichtenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shi, Yijiang, Fumou Sun, Yan Cheng, et al.. (2022). Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Molecular Cancer Therapeutics. 21(4). 502–510. 4 indexed citations

Vega, Mario I., Yijiang Shi, Patrick Frost, et al.. (2019). A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity. Molecular Cancer Therapeutics. 18(10). 1822–1831. 8 indexed citations

Shi, Yijiang, Tracy R. Daniels‐Wells, Patrick Frost, et al.. (2016). Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Research. 76(19). 5822–5831. 19 indexed citations

Hoang, Bao, et al.. (2016). SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism. Molecular Cancer Research. 14(4). 397–407. 10 indexed citations

Yoo, Esther M., et al.. (2014). Anti-CD138-Targeted Interferon Is a Potent Therapeutic Against Multiple Myeloma. Journal of Interferon & Cytokine Research. 35(4). 281–291. 21 indexed citations

Bardeleben, Carolyne, Sanjai Sharma, Joseph R. Reeve, et al.. (2013). Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells. Molecular Cancer Therapeutics. 12(7). 1310–1321. 29 indexed citations

Sharma, Sanjai, Wei Liao, Xiaofeng Zhou, David T. Wong, & Alan Lichtenstein. (2011). Exon 11 Skipping of E-Cadherin RNA Downregulates Its Expression in Head and Neck Cancer Cells. Molecular Cancer Therapeutics. 10(9). 1751–1759. 25 indexed citations

Bernath, Andrew, Tariq Bashir, Brent Holmes, et al.. (2011). Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma. Molecular Cancer Therapeutics. 10(12). 2244–2256. 15 indexed citations

Hoang, Bao, Angelica Benavides, Yijiang Shi, Patrick Frost, & Alan Lichtenstein. (2009). Effect of autophagy on multiple myeloma cell viability. Molecular Cancer Therapeutics. 8(7). 1974–1984. 124 indexed citations

10.

Jo, Oak D., Jheralyn Martin, Andrew Bernath, et al.. (2008). Heterogeneous Nuclear Ribonucleoprotein A1 Regulates Cyclin D1 and c-myc Internal Ribosome Entry Site Function through Akt Signaling. Journal of Biological Chemistry. 283(34). 23274–23287. 98 indexed citations

11.

Berenson, James R., Alan Lichtenstein, Lester Porter, et al.. (1996). Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. New England Journal of Medicine. 334(8). 488–493. 780 indexed citations breakdown →

12.

Lichtenstein, Alan, Yiping Tu, Catherine Fady, Robert Vescio, & James R. Berenson. (1995). Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells. Cellular Immunology. 162(2). 248–255. 244 indexed citations

13.

Fady, Catherine, Agnes Gardner, Joseph Gera, & Alan Lichtenstein. (1993). Interferon-?-induced increased sensitivity ofHER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events. Cancer Immunology Immunotherapy. 37(5). 329–336. 10 indexed citations

14.

Fady, Catherine, Agnes Gardner, Joseph Gera, & Alan Lichtenstein. (1993). Resistance ofHER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events. Cancer Immunology Immunotherapy. 36(5). 307–314. 3 indexed citations

15.

Gardner, Anne M., et al.. (1992). Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.. PubMed. 52(4). 764–9. 23 indexed citations

16.

Lichtenstein, Alan, et al.. (1991). Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor. The Journal of Immunology. 146(6). 2052–2058. 18 indexed citations

17.

Tu, Yiping, Fei Xu, A. Fleishman, et al.. (1990). BCL-X expression in multiple myeloma: possible indicator of chemoresistance.. Dialnet (Universidad de la Rioja). 58(2). 256–62. 201 indexed citations

18.

Lichtenstein, Alan, James Berenson, Joseph Gera, et al.. (1990). Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.. PubMed. 50(22). 7364–70. 53 indexed citations

19.

Lichtenstein, Alan, et al.. (1988). Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity.. The Journal of Immunology. 140(8). 2686–2694. 119 indexed citations

20.

Berek, Jonathan S., Neville F. Hacker, Alan Lichtenstein, et al.. (1986). Intraperitoneal recombinant α-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study. Seminars in Oncology. 13(3). 61–71. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact